Charles River’s experience with immuno-oncology drug development spans all phases, from target identification to IND. Utilizing the most effective combination of tools available to identify promising therapeutics, our broad range of models and support services allows clients to choose the most appropriate study design and screening method to identify the best options and optimize lead candidates. We seamlessly work with you through every step of the process to optimize your preclinical programs, determine the optimal outsourcing strategy that fits your needs and provide data in real time via our online portals.
Request Immuno-oncology Program Discussion »
Humanized Models: RKO Colon Carcinoma Growth in CD34-NSG